Bayer AG

BAYN

DE000BAY0017

Pharmaceuticals

Market Closed - Xetra Other stock markets 11:37:39 2024-04-19 am EDT			5-day change	1st Jan Change
26.32 ^EUR	+0.32%		-2.37%	-21.72%

Apr. 19	Bayer Signs Renewable Energy Purchase Deal for Six German Sites	MT
Apr. 19	Bayer: signs renewable energy supply contract	CF

BAYER AG : UBS remains its Buy rating

September 05, 2022 at 05:57 am EDT

UBS analyst Andrew Stott maintains his Buy rating on the stock. The target price is unchanged and still at EUR 96.

Latest news about Bayer AG

Bayer Signs Renewable Energy Purchase Deal for Six German Sites	Apr. 19	MT
Bayer: signs renewable energy supply contract	Apr. 19	CF
Capgemini: new platform implemented for Bayer	Apr. 19	CF
TV ratings: Bayer's Europa League success brings RTL many viewers	Apr. 19	DP
Bayer’s Investigational Gene Therapy for Heart Failure Gets US FDA Fast Track Designation	Apr. 18	MT
Bayer: fast-track procedure in cardiology in the USA	Apr. 18	CF
Study: US companies outpace Europe and Asia in research spending	Apr. 18	DP
Stifel Cuts Bayer PT, Keeps Hold Rating	Apr. 17	MT
Sat.1 to show top match between FC Bayern and Stuttgart	Apr. 17	DP
Conti slumps to early November level after figures	Apr. 17	DP
BAYER : Stifel lowers its target price	Apr. 17	CF
Bayer: presents results on Parkinson's disease	Apr. 16	CF
Bayer AG and Asklepios BioPharmaceutical, Inc Presents Results from the 18-Month Phase Ib Clinical Trial for AB-1005	Apr. 16	CI
Boehringer replaces Bayer as Germany's largest drugmaker on Jardiance gains	Apr. 16	RE
Eurozone Industrial Production Recovery Boosts German Stocks Amid Growing Tensions in Middle East	Apr. 15	MT
UBS Trims Bayer PT, Maintains Neutral Rating	Apr. 15	MT
BAYER AG : Barclays reaffirms its Neutral rating	Apr. 15	ZD
Nutrien Plans Exit From Argentina, Chile	Apr. 15	MT
BAYER : UBS lowers price target	Apr. 15	CF
BAYER AG : Gets a Neutral rating from JP Morgan	Apr. 15	ZD
BAYER : Another peer group tidy up	Apr. 14
Bayer's patent for blood thinner Xarelto invalid, UK court rules	Apr. 12	RE
BAYER AG : UBS sticks Neutral	Apr. 12	ZD
TV ratings: Future 'Charité' ends very weakly	Apr. 12	DP
Bayer and Hologic Collaborates to Deliver Contrast-Enhanced Mammography	Apr. 11	CI

Bayer AG is one of the world's leaders in designing, producing, and marketing pharmaceutical products and agrochemicals. Net sales are distributed by product family as follows: - agrochemicals (48.8%): herbicides, fungicides, insecticides, etc.; - pharmaceutical products (38%): intended for the prevention and treatment of cardiovascular and respiratory diseases, diabetes, nervous system disorders, etc.; - OTC products and nutritional supplements (12.7%); - other (0.5%). Net sales are distributed geographically as follows: Germany (5.1%), Switzerland (1.2%), Europe-Middle East-Africa (23.2%), the United States (30.6%), North America (3.5%), China (7.6%), Asia-Pacific (10%), Brazil (10.4%) and Latin America (8.4%).

Sector

Pharmaceuticals

Calendar

2024-04-26 - Annual General Meeting

Related indices

EURO STOXX 50 , STOXX EUROPE 600 (EUR) , DAX

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

BAYER : Another peer group tidy up

April 14, 2024 at 03:26 pm EDT

Bayer AG: Not out of the woods yet

March 06, 2024 at 10:46 am EST

More Strategies

Ratings for Bayer AG

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

26.32 EUR

Average target price

37.05 EUR

Spread / Average Target

+40.73%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
BAYER AG	-21.72%	27.49B
ELI LILLY AND COMPANY	+24.60%	672B
NOVO NORDISK A/S	+24.08%	550B
JOHNSON & JOHNSON	-5.63%	351B
MERCK & CO., INC.	+15.37%	317B
ABBVIE INC.	+7.38%	292B
ASTRAZENECA PLC	+3.26%	211B
NOVARTIS AG	+0.78%	203B
PFIZER, INC.	-9.69%	144B
AMGEN INC.	-6.63%	141B

Other Pharmaceuticals

Bayer AG

Equities

BAYN

DE000BAY0017

Pharmaceuticals

BAYER AG : UBS remains its Buy rating

Latest news about Bayer AG

Chart Bayer AG

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Bayer AG

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals